Every material Form 8-K RHYTHM PHARMACEUTICALS, INC. has filed with the SEC since June 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Rhythm Pharmaceuticals reported third-quarter 2026 net product revenue of $92.1 million from global IMCIVREE sales, up from $51.3 million a year earlier, and a net loss attributable to common stockholders of $42.4 million, or $0.61 per share, compared with $54.3 million, or $0.82 per share, a year earlier. The company also secured a five-year term loan facility providing access to up to $750 million and amended its bivamelagon license with LG Chem, which requires $350 million in fixed payments over four years, so shareholders face both stronger sales and a larger financing and licensing commitment.
Q3 2026 net product revenue was $92.1 million, up 29% from the second quarter of 2026 and up from $51.3 million in Q3 2025.
Q3 2026 net loss attributable to common stockholders was $42.4 million, or $0.61 per share, versus $54.3 million, or $0.82 per share, in Q3 2025.
Cash, cash equivalents and short-term investments were $320.9 million as of September 30, 2026, excluding the $250 million initial draw on the term loan and a $70 million payment due to LG Chem.
Non-GAAP operating expenses for 2026 are expected to be $360 million to $380 million.
Rhythm Pharmaceuticals reported second quarter 2026 net product revenue of $71.3 million from IMCIVREE, up from $48.5 million a year earlier, and a net loss attributable to common stockholders of $50.4 million, or $(0.73) per share, compared with $(0.75) per share a year earlier. The company also released preliminary Phase 2 data showing an 11.6% mean BMI reduction at 16 weeks for RM-718 in a small group of patients with acquired hypothalamic obesity, which shareholders may watch as the program advances.
Q2 2026 net product revenue was $71.3 million, versus $48.5 million in Q2 2025; U.S. revenue was $51.0 million.
Q2 2026 net loss attributable to common stockholders was $50.4 million, or $(0.73) per share, versus $48.0 million, or $(0.75) per share, in Q2 2025.
RM-718 showed a mean BMI reduction of 11.6% from baseline at 16 weeks (n=7) in the ongoing Phase 2 trial, which enrolled eleven patients with acquired HO.
Cash, cash equivalents and short-term investments were $330.9 million as of June 30, 2026, and the company expects these to fund planned operations for at least 24 months.
Rhythm Pharmaceuticals released interim six-month data from an exploratory Phase 2 trial of setmelanotide in Prader-Willi syndrome, with 17 patients on active therapy and a data cut-off of May 7, 2026. The company reported mean BMI reductions, fat loss with preserved lean mass, and hyperphagia improvements, and said the results reinforce its rationale for Phase 3 development in PWS. The trial is small, open-label and ongoing for 52 weeks, so the results do not yet establish efficacy.
Mean BMI reduction at Month 6 was -3.06% (n=17), with -3.11% in adults (n=10) and -3.00% in pediatric patients (n=7)
Mean fat mass change was -4.19% and mean lean mass change was +0.74% across 16 patients with DEXA data
Eight of 10 patients with moderate to severe hyperphagia achieved a 7-point or greater HQ-CT improvement
The 52-week trial remains ongoing, with 17 patients on active therapy as of June 12, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every RHYTHM PHARMACEUTICALS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →